← Back to headlines
Fortress Biotech's Cyprium Sells PRV for $205 Million
Fortress Biotech's subsidiary, Cyprium Therapeutics, has entered an agreement to sell its Priority Review Voucher (PRV) for $205 million.
24 Feb, 13:53 — 24 Feb, 13:53
ℹOnly 1 source covers this story
